The International Pharmaceutical Federation Education Initiative (FIPEd) launched the 2013 FIPEd Global Education Report (available at: www.fip.org/educationreports) in September 2013. This is the first publication …
According to the Bylaws of the American Association of Colleges of Pharmacy (AACP), the Academic Affairs Committee shall consider the intellectual, social, and personal aspects …
As Legend Biotech and Johnson & Johnson’s multiple myeloma cell therapy prospect nears the FDA finish line, the companies are moving to carve out a manufacturing …
As Horizon Therapeutics’ one-and-a-half-year-old thyroid eye disease med Tepezza starts to spread its wings, the drugmaker is standing up in-house manufacturing to help blunt any further …
As Bristol Myers Squibb looks to guard Celgene’s top-selling cancer drug Revlimid from copycat competition, the company has inked a series of deals to welcome …
Amgen’s high-profile PCSK9 patent fight with Sanofi and Regeneron has attracted a who’s who of biopharma observers over the years, with many top companies voicing support for each side. Now, Amgen …
In rapidly developing a COVID-19 vaccine—and a highly effective one at that—Novavax got the hard part right. But the logistics of manufacturing the vaccine has proven …
For three years, Merck & Co.’s Keytruda has been the onlyimmuno-oncology drug allowed to treat cervical cancer. Now, thanks to a new clinical win, Merck aims to …
Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year …
Despite back-to-back phase 3 trial wins in atopic dermatitis, Incyte’s ruxolitinib cream isn’t immune to class-wide JAK inhibitor safety scrutiny. Incyte on Friday disclosed that the FDA has put off …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
